Skip to content
  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
PHP Toggle Menu

Category: BT-001

First Patient Dosed in Phase 1 Trial Evaluating Transgene’s and BioInvent’s BT-001 in Patients with Rectal Cancer

BT-001 rectacl cancer

Published 5 November 2026
Categorized as 2026, 2026, BT-001, Invir.IO, Press release

Transgene and BioInvent’s Armed Oncolytic Virus BT-001 Shows Positive Local, Abscopal, and Sustained Antitumoral Activity in Advanced Refractory Tumors

ESMO Poster

Published 20 October 2025
Categorized as 2025, BT-001, Press release

Updated clinical results of BT-001, an oncolytic virus expressing an anti-CTLA4 mAb,administered in combination with pembrolizumab in patients with advanced solid tumors

C. Lebbe, et al. ESMO 2025 Abstract available on ESMO website – Download the abstract – Download the Poster

Published 20 October 2025
Categorized as 2025, BT-001, Publication, publication key en

Transgene and BioInvent to Present Translational Data and Updated Clinical Results on Armed Oncolytic Virus BT-001, at ESMO 2025

ESMO Abstract

Published 13 October 2025
Categorized as 2025, BT-001, Press release

Transgene and BioInvent to Present Updated Data on Armed Oncolytic virus BT-001 at ESMO 2025

ESMO 2025

Published 27 July 2025
Categorized as 2025, BT-001, Invir.IO, Press release

Initial clinical results of BT-001, an oncolytic virus expressing an anti-CTLA4 mAb, administered as single agent and in combination with pembrolizumab in patients with advanced solid tumors

S. Champiat, et al. ESMO 2024  Abstract available on the ESMO website – Download the abstract and the poster

Published 14 September 2024
Categorized as 2024, BT-001, Publication

Transgene and BioInvent’s Oncolytic Virus BT-001 Shows Promising Antitumor Activity in Ongoing Phase I/IIa Trial in Solid Tumors that Failed Previous Treatment

BT-001 ESMO

Published 14 September 2024
Categorized as 2024, BT-001, categorie-orpheline, dates, dates, Press release

Transgene and BioInvent to Present Promising Initial Phase I/IIa Data on Oncolytic Virus, BT-001, at ESMO 2024

ESMO ABSTRACT

Published 9 September 2024
Categorized as 2024, BT-001, dates, Press release

Transgene and BioInvent to Present Poster on Oncolytic Virus, BT-001, at ESMO 2024

BT-001 ESMO 2024

Published 22 July 2024
Categorized as 2024, BT-001, categorie-orpheline, dates, dates, Press release

Transgene and BioInvent – First patient treated in Part B of Phase I trial assessing the novel oncolytic virus BT-001 in combination with KEYTRUDA®(pembrolizumab)

Transgene and BioInvent – first patient treated in Part B of Phase I trial

Published 10 October 2023
Categorized as 2023, BT-001, categorie-orpheline, dates, dates, Press release

Posts pagination

Page 1 … Page 4 Older posts
Get to know us

About us

myvac

Pipeline

Investors

Partnering

Company

Career

ESG

Suppliers

Contacts

Legal documents

Legal notices

Privacy Policy

Ethics and compliance

Cookie policy

  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
Menu